chipswsop| Concino: Plans to sign a product transfer and technology license agreement with Shanghai Pharmaceutical Concino

Newsletter summary

Kangxinuo: plans to sign product transfer and technology license agreement with Shangyao Kangxinuo Securities Times e Company News, Kangxinuo (688185) announced on the evening of April 29th, the company intends to sign the "Product transfer and Technology license" with Shanghai Shangyao Kangxinuo Biopharmaceutical Co., Ltd.Chipswsop...

Text of news flash

Kangxinuo: plans to sign product transfer and technology license agreement with Shangyao Kangxinuo Securities Times (688185) announced on the evening of April 29th, the company intends to sign the Product transfer and Technology license Agreement with Shanghai Shangyao Kangxinuo Biopharmaceutical Co., Ltd. (referred to as "Shangyao Kangxinuo"). The agreed company will recombine Ebola virus disease vaccine (adenovirus vector) (referred to as "Ad5-EBOV") and transfer products worldwide.ChipswsopThe commercial rights and interests of Shangyao Kangxinuo will be transferred to Shangyao Kangxinuo, and commercial cooperation will be reached by way of license, so that Shangyao Kangxinuo has the right to use the licensed technology related to the transferred products globally. Since the approval, the transfer of the product has not generated sales revenue. The company disclosed on the same day that its net profit in the first quarter of 2024 was a loss of 170 million yuan.